Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 313,683
  • Shares Outstanding, K 159,230
  • Annual Sales, $ 6,160 K
  • Annual Income, $ -29,540 K
  • 36-Month Beta 2.56
  • Price/Sales 51.94
  • Price/Cash Flow N/A
  • Price/Book 2.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +8.20%
on 11/16/17
2.08 -4.81%
on 12/07/17
+0.13 (+7.03%)
since 11/15/17
3-Month
1.74 +13.79%
on 11/14/17
2.36 -16.10%
on 10/06/17
-0.22 (-10.00%)
since 09/15/17
52-Week
1.74 +13.79%
on 11/14/17
3.15 -37.14%
on 05/16/17
-0.12 (-5.71%)
since 12/15/16

Most Recent Stories

More News
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting

Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented

GERN : 1.98 (+0.51%)
Biotech's Flying Under The Radar

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments...

ESPR : 58.38 (+1.07%)
AEZS : 2.08 (-6.31%)
PPCB : 0.1200 (-23.81%)
GERN : 1.98 (+0.51%)
CPRX : 4.08 (-0.49%)
Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017

Geron Corporation (Nasdaq:GERN) today announced that the company's analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017. The...

GERN : 1.98 (+0.51%)
Factors of Influence in 2018, Key Indicators and Opportunity within Visa, The Kraft Heinz, AbbVie, Fossil Group, Geron, and Universal Insurance Holdings -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Visa Inc. (NYSE:V), The Kraft...

FOSL : 6.86 (-1.01%)
UVE : 26.10 (+2.96%)
V : 113.82 (+0.80%)
KHC : 79.54 (+0.71%)
ABBV : 97.45 (+1.19%)
GERN : 1.98 (+0.51%)
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes

Geron Corporation (Nasdaq:GERN) today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in transfusion dependent patients...

GERN : 1.98 (+0.51%)
Today's Research Reports on Trending Tickers: Gilead Sciences and Geron Corporation

NEW YORK, NY / ACCESSWIRE / November 15, 2017 / U.S. markets fell Tuesday on slumping commodity prices, with U.S. crude oil posting its largest one day drop in over a month. The Dow Jones Industrial Average...

GILD : 75.57 (+1.65%)
GERN : 1.98 (+0.51%)
Geron Announces November Investor Conference Presentation Webcasts

Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:

GERN : 1.98 (+0.51%)
Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

AGEN : 3.56 (+1.14%)
JNJ : 142.46 (+0.57%)
EXEL : 26.10 (+0.58%)
GERN : 1.98 (+0.51%)
Geron Corporation Reports Third Quarter 2017 Financial Results

Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2017.

GERN : 1.98 (+0.51%)
Geron Corporation to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 1, 2017 / Geron Corporation (NASDAQ: GERN) will be discussing their earnings results in their Q3 Earnings Call to be held on November 1, 2017 at 4:30 PM Eastern Time....

GERN : 1.98 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking...

See More

Key Turning Points

2nd Resistance Point 2.02
1st Resistance Point 2.00
Last Price 1.98
1st Support Level 1.97
2nd Support Level 1.96

See More

52-Week High 3.15
Fibonacci 61.8% 2.61
Fibonacci 50% 2.45
Fibonacci 38.2% 2.28
Last Price 1.98
52-Week Low 1.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.